entity

EMPAGLIFLOZIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about EMPAGLIFLOZIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

74Connections
0Hypotheses
0Analyses
50Outgoing
13Incoming

Wiki Pages (8)

Knowledge base pages for this entity

Taisho Pharmaceutical

company · 2715 words

sglt2-inhibitors-neurodegeneration

therapeutic · 2458 words

Progressive Supranuclear Palsy Treatment Landscape

mechanism · 2427 words

Metabolic Dysfunction (Type 3 Diabetes) Hypothesis in Alzheimer's Disease

hypothesis · 1806 words

Astrocyte Metabolic Modulation Therapy for Neurodegeneration

therapeutic · 1724 words

Outgoing (61)

TargetRelationTypeStr
AMPKactivatesprotein0.80
PARP1activatesgene0.65
HYDROGEN PEROXIDEprotects_againstphenotype0.65
HYDROGEN PEROXIDEactivatesphenotype0.65
BDNFregulatesgene0.65

Incoming (13)

SourceRelationTypeStr
DEMENTIAprotects_againstdisease0.65
DEMENTIAinhibitsdisease0.65
ATPactivatesphenotype0.65
TAU PHOSPHORYLATIONassociated_withphenotype0.50
NEUROINFLAMMATIONassociated_withphenotype0.50

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found